Aldeyra Therapeutics (ALDX) Stock Forecast, Price Target & Predictions
ALDX Stock Forecast
Aldeyra Therapeutics stock forecast is as follows: an average price target of $10.00 (represents a 65.84% upside from ALDX’s last price of $6.03) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ALDX Price Target
The average price target for Aldeyra Therapeutics (ALDX) is $10.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 65.84% upside from ALDX's last price of $6.03.
ALDX Analyst Ratings
According to 2 Wall Street analysts, Aldeyra Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ALDX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Aldeyra Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 03, 2024 | Justin Kim | Oppenheimer | $10.00 | $3.55 | 181.69% | 65.84% |
| Apr 02, 2024 | Matt Caufield | H.C. Wainwright | $10.00 | $3.27 | 205.81% | 65.84% |
The latest Aldeyra Therapeutics stock forecast, released on Apr 03, 2024 by Justin Kim from Oppenheimer, set a price target of $10.00, which represents a 181.69% increase from the stock price at the time of the forecast ($3.55), and a 65.84% increase from ALDX last price ($6.03).
Aldeyra Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $10.00 |
| Last Closing Price | $6.03 | $6.03 | $6.03 |
| Upside/Downside | -100.00% | -100.00% | 65.84% |
In the current month, the average price target of Aldeyra Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Aldeyra Therapeutics's last price of $6.03. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 03, 2024 | Oppenheimer | - | Outperform | Upgrade |
| Jun 09, 2022 | Citigroup | Buy | Buy | Hold |
Aldeyra Therapeutics's last stock rating was published by Oppenheimer on Apr 03, 2024. The company Upgrade its ALDX rating from "null" to "Outperform".
Aldeyra Therapeutics Financial Forecast
Aldeyra Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $392.62K | - |
| Avg Forecast | - | - | - | - | $33.17M | - | - | $1.20M | $3.00M | $-46.00 |
| High Forecast | - | - | - | - | $33.17M | - | - | $1.20M | $3.00M | $-46.00 |
| Low Forecast | - | - | - | - | $33.17M | - | - | $1.20M | $3.00M | $-46.00 |
| # Analysts | 4 | 5 | 2 | 2 | 7 | 3 | - | 1 | 4 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 0.13% | - |
Aldeyra Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.20M, with a low forecast of $1.20M, and a high forecast of $1.20M. ALDX's average Quarter revenue forecast represents a 205.64% increase compared to the company's last Quarter revenue of $392.62K (Dec 23).
Aldeyra Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 7 | 3 | - | 1 | 4 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-13.97M | $-15.31M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | $-14.72M |
| High Forecast | - | - | - | - | - | - | - | - | - | $-11.78M |
| Low Forecast | - | - | - | - | - | - | - | - | - | $-17.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% |
undefined analysts predict ALDX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Aldeyra Therapeutics's previous annual EBITDA (undefined) of $NaN.
Aldeyra Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 7 | 3 | - | 1 | 4 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-5.45M | $-15.79M |
| Avg Forecast | $-15.45M | $-15.45M | $-13.67M | $-13.67M | $9.61M | $-14.68M | $-12.26M | $-6.57M | $-6.57M | $-15.19M |
| High Forecast | $-15.45M | $-15.45M | $-13.67M | $-13.67M | $9.61M | $-9.40M | $-8.17M | $-6.57M | $-5.63M | $-12.15M |
| Low Forecast | $-15.45M | $-15.45M | $-13.67M | $-13.67M | $9.61M | $-18.21M | $-16.34M | $-6.57M | $-6.88M | $-18.22M |
| Surprise % | - | - | - | - | - | - | - | - | 0.83% | 1.04% |
Aldeyra Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ALDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Aldeyra Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 7 | 3 | - | 1 | 4 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $1.80M | $2.55M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - |
Aldeyra Therapeutics's average Quarter SG&A projection for Mar 24 is -, based on 1 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ALDX last annual SG&A of $1.80M (Dec 23).
Aldeyra Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 7 | 3 | - | 1 | 4 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.09 | $-0.27 |
| Avg Forecast | $-0.26 | $-0.26 | $-0.23 | $-0.23 | $0.16 | $-0.25 | $-0.21 | $-0.11 | $-0.11 | $-0.26 |
| High Forecast | $-0.26 | $-0.26 | $-0.23 | $-0.23 | $0.16 | $-0.16 | $-0.14 | $-0.11 | $-0.09 | $-0.26 |
| Low Forecast | $-0.26 | $-0.26 | $-0.23 | $-0.23 | $0.16 | $-0.31 | $-0.28 | $-0.11 | $-0.12 | $-0.26 |
| Surprise % | - | - | - | - | - | - | - | - | 0.84% | 1.03% |
According to undefined Wall Street analysts, Aldeyra Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ALDX previous annual EPS of $NaN (undefined).
Aldeyra Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LXRX | Lexicon Pharmaceuticals | $1.70 | $10.00 | 488.24% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ETNB | 89bio | $8.48 | $22.00 | 159.43% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| IBRX | ImmunityBio | $3.58 | $8.00 | 123.46% | Sell |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| TARS | Tarsus Pharmaceuticals | $33.26 | $61.00 | 83.40% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| ALDX | Aldeyra Therapeutics | $6.03 | $10.00 | 65.84% | Buy |
| ETON | Eton Pharmaceuticals | $5.15 | $8.50 | 65.05% | Buy |
| TVTX | Travere Therapeutics | $13.48 | $21.60 | 60.24% | Buy |
| PHAT | Phathom Pharmaceuticals | $18.30 | $25.83 | 41.15% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| ARDX | Ardelyx | $6.31 | $8.75 | 38.67% | Buy |
| MCRB | Seres Therapeutics | $1.00 | $1.25 | 25.00% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
ALDX Forecast FAQ
Is Aldeyra Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Aldeyra Therapeutics (ALDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ALDX's total ratings.
What is ALDX's price target?
Aldeyra Therapeutics (ALDX) average price target is $10 with a range of $10 to $10, implying a 65.84% from its last price of $6.03. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Aldeyra Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ALDX stock, the company can go up by 65.84% (from the last price of $6.03 to the average price target of $10), up by 65.84% based on the highest stock price target, and up by 65.84% based on the lowest stock price target.
Can Aldeyra Therapeutics stock reach $9?
ALDX's average twelve months analyst stock price target of $10 supports the claim that Aldeyra Therapeutics can reach $9 in the near future.
What are Aldeyra Therapeutics's analysts' financial forecasts?
Aldeyra Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $34.37M (high $34.37M, low $34.37M), average EBITDA is $0 (high $0, low $0), average net income is $-23.904M (high $-14.533M, low $-31.513M), average SG&A $0 (high $0, low $0), and average EPS is $-0.402 (high $-0.245, low $-0.53). ALDX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-58.226M (high $-58.226M, low $-58.226M), average SG&A $0 (high $0, low $0), and average EPS is $-0.98 (high $-0.98, low $-0.98).
Did the ALDX's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Dec 2023), Aldeyra Therapeutics's revenue was $392.62K, missing the average analysts' forecast of $3M by -86.91%. The company's EBITDA was $-13.975M, beating the average prediction of $0 by 0%. Aldeyra Therapeutics's net income was $-5.449M, missing the average estimation of $-6.566M by -17.01%. The company's SG&A was $1.8M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-0.0924, missing the average prediction of $-0.111 by -16.40%